These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 8923308)
21. Resistance to activated protein C: a common anticoagulant deficiency in patients with venous leg ulceration. Peus D; Pittelkow MR Br J Dermatol; 1997 Aug; 137(2):322-3. PubMed ID: 9292102 [No Abstract] [Full Text] [Related]
22. Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis. Mandel H; Brenner B; Berant M; Rosenberg N; Lanir N; Jakobs C; Fowler B; Seligsohn U N Engl J Med; 1996 Mar; 334(12):763-8. PubMed ID: 8592550 [TBL] [Abstract][Full Text] [Related]
23. Activated protein C resistance: the commonest hereditary hypercoagulation disorder. Sulaiman-Shoab S Br J Surg; 1998 Aug; 85(8):1161. PubMed ID: 9718029 [No Abstract] [Full Text] [Related]
24. Resistance to activated protein C in unselected patients with arterial and venous thrombosis. Faioni EM; Razzari C; Martinelli I; Panzeri D; Franchi F; Mannucci PM Am J Hematol; 1997 Jun; 55(2):59-64. PubMed ID: 9208999 [TBL] [Abstract][Full Text] [Related]
25. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. Martinelli I; Sacchi E; Landi G; Taioli E; Duca F; Mannucci PM N Engl J Med; 1998 Jun; 338(25):1793-7. PubMed ID: 9632445 [TBL] [Abstract][Full Text] [Related]
26. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Hallak M; Senderowicz J; Cassel A; Shapira C; Aghai E; Auslender R; Abramovici H Am J Obstet Gynecol; 1997 Apr; 176(4):889-93. PubMed ID: 9125617 [TBL] [Abstract][Full Text] [Related]
27. [APC resistance and blood coagulation factor V mutation in Finnish thrombotic patients]. Hakala L; Vahtera E; Krusius T; Rasi V Duodecim; 1995; 111(22):2143-51. PubMed ID: 9841174 [No Abstract] [Full Text] [Related]
28. Fatal cerebral venous sinus thrombosis associated with the factor V Leiden mutation and the use of oral contraceptives. Bridey F; Wolff M; Laissy JP; Morin V; Lefebvre M; de Prost D Thromb Haemost; 1995 Nov; 74(5):1382. PubMed ID: 8607129 [No Abstract] [Full Text] [Related]
29. Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Dahlbäck B Thromb Haemost; 1995 May; 73(5):739-42. PubMed ID: 7482395 [No Abstract] [Full Text] [Related]
30. Activated-protein-C resistance in cancer patients. Green D; Maliekel K; Sushko E; Akhtar R; Soff GA Haemostasis; 1997; 27(3):112-8. PubMed ID: 9306127 [TBL] [Abstract][Full Text] [Related]
31. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Nowak-Göttl U; Koch HG; Aschka I; Kohlhase B; Vielhaber H; Kurlemann G; Oleszcuk-Raschke K; Kehl HG; Jürgens H; Schneppenheim R Br J Haematol; 1996 Mar; 92(4):992-8. PubMed ID: 8616099 [TBL] [Abstract][Full Text] [Related]
32. [A new hereditary cause of portal vein thrombosis: the abnormal resistance to activated protein C by the Arg 506-->Gln mutation of the gene of factor V]. Levoir D; Aubertin JM; Alhenc-Gelas M; Bloch F; Becheur H; Petite JP Gastroenterol Clin Biol; 1995; 19(8-9):729-31. PubMed ID: 8522125 [TBL] [Abstract][Full Text] [Related]
33. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Martinelli I; Landi G; Merati G; Cella R; Tosetto A; Mannucci PM Thromb Haemost; 1996 Mar; 75(3):393-4. PubMed ID: 8701395 [TBL] [Abstract][Full Text] [Related]
34. [Changes in the blood clotting system of families of patients with cerebrovascular thrombosis]. Murav'eva ZM Zh Nevropatol Psikhiatr Im S S Korsakova; 1971; 71(1):51-4. PubMed ID: 5563635 [No Abstract] [Full Text] [Related]
35. Factor V Leiden mutation in cerebral venous thrombosis. Zuber M; Toulon P; Marnet L; Mas JL Stroke; 1996 Oct; 27(10):1721-3. PubMed ID: 8841317 [TBL] [Abstract][Full Text] [Related]
36. Mutation in blood coagulation factor V associated with resistance to activated protein C. Bertina RM; Koeleman BP; Koster T; Rosendaal FR; Dirven RJ; de Ronde H; van der Velden PA; Reitsma PH Nature; 1994 May; 369(6475):64-7. PubMed ID: 8164741 [TBL] [Abstract][Full Text] [Related]
37. Activated protein C resistance: What have we learned now that the dust has settled? Petäjä JM; Griffin JH Ann Med; 1997 Dec; 29(6):469-72. PubMed ID: 9562511 [TBL] [Abstract][Full Text] [Related]
38. Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Press RD; Liu XY; Beamer N; Coull BM Stroke; 1996 Jan; 27(1):44-8. PubMed ID: 8553401 [TBL] [Abstract][Full Text] [Related]
39. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis. Gessoni G; Valverde S Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946 [TBL] [Abstract][Full Text] [Related]
40. Factor V R506Q gene mutation analysis by PCR-RFLP: optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls. Voelkerding KV; Wu L; Williams EC; Hoffman SM; Sabatini LM; Borcherding WR; Huber S Am J Clin Pathol; 1996 Jul; 106(1):100-6. PubMed ID: 8701917 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]